N-Glycans vs O-Glycans: The Two Main Types of Glycosylation and What Each Tells You About Health

N-glycans and O-glycans are the two primary types of glycosylation — the biological process by which complex sugars (glycans) are attached to proteins and lipids to regulate their function. The distinction lies in where the glycan chain attaches to the protein backbone: N-glycans bind to nitrogen atoms on the amino acid asparagine, while O-glycans bind to oxygen atoms on serine or threonine residues. Both types are post-translational modifications, meaning they occur after a protein is synthesized from RNA, and both are tightly enzymatically controlled processes, not random chemical events.

This distinction matters clinically because the type of glycosylation determines which proteins are modified, how those proteins function, and what biological signals they carry. Glycosylation is not a minor biochemical footnote: most proteins in the human body are glycoproteins, meaning they cannot function without their attached glycan structures. Understanding which type of glycosylation is relevant to a given health question determines which biomarker is worth measuring.

Want to understand what glycans are and why they matter for your health? Read our foundational guide: Glycans: The Sugars That Reveal Your Biological Age and Immune Health.

What Is N-Linked Glycosylation, and Which Proteins Does It Affect?

N-linked glycosylation is the attachment of a complex sugar chain to the nitrogen atom of an asparagine residue within a specific three-amino-acid sequence on the protein backbone, and it requires that conserved sequence to occur. This is a strictly regulated, enzymatically mediated process — the glycan attaches at a defined site, not randomly. The result is a glycoprotein whose function, stability, and biological activity are shaped by the structure of the attached glycan.

Immunoglobulin G (IgG), which is the dominant antibody in human blood and the central protein of the adaptive immune system, is N-glycosylated. The glycans attached to IgG at its Fc region are N-linked, and their composition directly determines whether IgG triggers a pro-inflammatory or anti-inflammatory immune response. When those glycans carry sialic acid (a terminal sugar residue), IgG acts in an anti-inflammatory direction; when sialic acid and galactose are absent, the same IgG molecule activates inflammatory pathways including the complement cascade.

"Changing a single monosaccharide in a glycan can completely convert the function of an immunoglobulin from pro-inflammatory to anti-inflammatory. The simple addition or removal of a sugar on the core of the glycan can either activate or prevent antibody-dependent cellular cytotoxicity — making both monoclonal drugs and our native antibodies up to a hundred times more or less efficient."

— Prof. Gordan Lauc, Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb

This single structural difference, the presence or absence of specific terminal sugars on an N-glycan, is the molecular mechanism GlycanAge measures across 29 distinct glycan structures.

What Is O-Linked Glycosylation, and What Does It Regulate?

O-linked glycosylation is the attachment of a sugar chain to the oxygen atom of serine or threonine residues on a protein, and unlike N-glycosylation, it does not require a conserved amino acid sequence. O-glycans tend to be structurally simpler than N-glycans and are found extensively on mucins (the proteins that form protective mucus layers), cell-surface receptors, and nuclear proteins involved in signaling. O-GlcNAcylation, a specific form of O-linked glycosylation involving a single N-acetylglucosamine sugar, functions as a nutrient and stress sensor inside cells, modulating transcription, protein degradation, and metabolic signaling.

Both N- and O-glycosylation are post-translational modifications that integrate genetic, epigenetic, and environmental signals into protein function in real time. As Prof. Gordan Lauc, CSO and Co-Founder of GlycanAge, has described it: glycans allow biology to change the function of a molecule in real time without needing to alter genes or turn gene expression on and off. This is a level of regulatory flexibility that neither the genome nor the epigenome can match.

Why Does GlycanAge Focus on N-Glycosylation of IgG Specifically?

GlycanAge measures N-linked glycosylation of IgG because IgG glycans are the most validated, most clinically informative, and most intervention-responsive glycan biomarker identified to date. IgG is the central protein of the adaptive immune system, and its glycan composition directly controls the inflammatory tone of the immune response. The ratio of pro-inflammatory to anti-inflammatory IgG glycans shifts predictably with age, chronic disease, lifestyle, and medical interventions, making it a reliable signal of biological aging rather than a snapshot of acute physiology.

The GlycanAge test analyzes 29 different IgG glycan structures from a finger-prick blood sample, measuring the balance between short, pro-inflammatory glycan chains (characterized by low galactosylation and absent sialylation) and longer, anti-inflammatory chains. This balance is what the three primary GlycanAge indexes — Glycan Shield, Glycan Youth, and Glycan Mature — use to produce the biological age result, supported by two additional indexes, Glycan Median and Glycan Bisection, which provide context on lifestyle, genetic, and disease-pattern associations. The science behind this approach is built on over 30 years of glycobiology research and a substantial body of published peer-reviewed studies, including the foundational glycan clock paper first published in 2013.

How Is Glycosylation Different from Glycation and Why Does the Confusion Matter?

Glycosylation and glycation are fundamentally different processes, and conflating them leads to misinterpretation of what a glycan-based biological age test actually measures. Glycation is the random, non-enzymatic attachment of a single glucose molecule to a protein (the process measured by HbA1c in diabetes monitoring) and it typically causes damage to protein function and stability. It occurs in states of elevated blood sugar and is not genetically regulated.

Glycosylation, by contrast, is a sophisticated, enzymatically controlled process in which complex multi-sugar structures are assembled and attached to proteins at precisely defined sites. A single N-glycan on IgG is a structurally elaborate, branched architecture built from multiple individual sugar molecules — a level of molecular complexity that has no equivalent in the simple glucose attachment that constitutes glycation. This is not damage, but a function. GlycanAge measures glycosylation, not glycation, and the distinction is the difference between measuring a regulated biological signal and measuring the byproduct of metabolic stress.

Can Glycosylation Patterns Actually Change and How Quickly?

Glycosylation patterns are dynamic and respond to lifestyle, hormonal, and pharmacological interventions within three to six months. This responsiveness is what makes IgG glycan measurement clinically actionable: a practitioner can baseline a patient, initiate an intervention, whether dietary, pharmacological, or hormonal, and retest within six months to determine whether the glycan profile has shifted in a favorable direction. Prof. Lauc has tracked his own GlycanAge for nearly a decade and observed that dietary changes, weight fluctuation, and periods of high stress each produce measurable shifts in his glycan composition.

This responsiveness distinguishes glycan-based biological age measurement from epigenetic clocks, where intervention data is frequently conflicting, and from static DNA tests, which reflect genetic potential that does not change regardless of lifestyle. Glycans sit at the intersection of genetics, epigenetics, and environment, integrating all three into a single, measurable, modifiable signal.

"Glycans integrate genetic, epigenetic, and environmental factors. At the moment we either measure metabolites and enzymes that change extremely quickly, or we look at genes that do not change at all. We are missing an intermediate — something between these day-to-day altering molecules and genes that never change. That intermediate is glycans."

— Prof. Gordan Lauc, Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb

What Should a Functional Medicine Practitioner Do With This Information?

For functional medicine practitioners, the practical implication is straightforward: IgG N-glycosylation is the most clinically validated glycan biomarker for tracking immune aging and chronic inflammation, and it responds to interventions on a timeline that fits clinical practice.

"The best way to determine whether something works is to have a person make an intervention — introduce a therapy, a new drug, a hormone, or simply start exercising or meditating — and then check what happened after three to six months."

— Prof. Gordan Lauc, Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb

Baseline your patient before initiating a protocol, whether that is a dietary intervention, HRT, a supplement regimen, or a stress-reduction programme, and retest at six months to determine whether the intervention is producing measurable biological change.

GlycanAge provides an objective, personalized measurement that complements standard blood panels. Where generic blood biomarkers capture hourly and daily fluctuation, IgG glycan patterns reflect the chronic, low-grade inflammatory biology that drives age-related disease. This is the signal that standard panels miss entirely. As a clinical tool, GlycanAge is not a diagnostic instrument; it is a validated biomarker for tracking immune aging and intervention effectiveness, designed to be interpreted alongside clinical history and other health data.

If you work with patients who want to know whether their interventions are working at a biological level, GlycanAge gives you the measurement infrastructure to answer that question with evidence. The Healthcare Providers page walks through how to integrate GlycanAge into your clinical workflow, from baselining to repeat testing and result interpretation.

Explore GlycanAge for Healthcare Providers →

External Sources

• https://pubmed.ncbi.nlm.nih.gov/24325898/ — Krištić J, et al. Glycans Are a Novel Biomarker of Chronological and Biological Ages. The Journals of Gerontology: Series A, 2014.

• https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test — The A1C Test & Diabetes. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH.

• https://www.ncbi.nlm.nih.gov/books/NBK26821/ — An Introduction to Molecular Biology: Post-Translational Modification of Proteins. NCBI Bookshelf.